Research for Chengda Biotechnology Acquires Recombinant Quadrivalent Enterovirus Vaccine Technology for RMB 46 Million – Strengthening Its HFMD Vaccine Pipeline Beyond EV71 - aVenture Research
Insight, China's Pharmaceutical Industry
Chengda Biotechnology Acquires Recombinant Quadrivalent Enterovirus Vaccine Technology for RMB 46 Million – Strengthening Its HFMD Vaccine Pipeline Beyond EV71
Liaoning Chengda Biotechnology Co., Ltd. (SHA: 688739) announced that it has signed a Recombinant Quadrivalent Enterovirus Vaccine Technology Transfer Agreement with Viltech (Beijing) Biotechnology Co., Ltd. Under the agreement, Chengda Biotech will acquire all rights and interests in the Recombinant Quadrivalent Enterovirus Vaccine (Hansenula polymorpha) project for a technology transfer fee of RMB 46 million (≈ US$6.5 million). The asset — which has already received an approval notice for clin